Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2015 Aug;74(8):778–790. doi: 10.1097/NEN.0000000000000216

Figure 6.

Figure 6

Combination therapy of the bromodomain inhibitor JQ1 and the γ-secretase inhibitor MRK003 leads to increased cell death. (A) Western blot of MYC and MYCN expression in SF7761 and JHH DIPG1 cells after 4 days of treatment with JQ1 showing that expression decreases in a dose-dependent manner. (B) Percent viability of SF7761 and JHH DIPG1 cells after 5 days of treatment with JQ1, normalized to DMSO control. *p < 0.05; **p < 0.01 by ANOVA. (C) Quantification of percent bromodeoxyuridine (BrdU) positivity in SF7761, JHH DIPG1, and SU DIPG XIII treated with JQ1 for 48 hours followed by MRK003 treatment for 48 hours, or JQ1 alone for 96 hours, or MRK003 alone for 48 hours. *p < 0.05; **p < 0.01 by ANOVA. (D) Quantification of percent cleaved caspase 3 (CC3) positivity in SF7761, JHH-DIPG1, and SU DIPG XIII treated with JQ1 for 48 hours followed by MRK003 for 48 hours, or JQ1 alone for 96 hours, or MRK003 alone for 48 hours). *p < 0.05; **p < 0.01; ***p < 0.001 by ANOVA.